Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice (Q41539694)

2 October 2017

title

Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice (English)

1 reference

2 October 2017

main subject

Streptococcus pneumoniae

1 reference

Lingbin Zeng

1

1 reference

2 October 2017

Yusi Liu

2

1 reference

2 October 2017

Hong Wang

3

1 reference

2 October 2017

Pu Liao

4

1 reference

2 October 2017

Zhixin Song

5

1 reference

2 October 2017

Song Gao

6

1 reference

2 October 2017

Yingying Wu

7

1 reference

2 October 2017

Xuemei Zhang

8

1 reference

2 October 2017

Yibing Yin

9

1 reference

2 October 2017

Wenchun Xu

10

1 reference

2 October 2017

language of work or name

English

0 references

publication date

14 January 2015

1 reference

2 October 2017

1 reference

2 October 2017

volume

33

1 reference

2 October 2017

issue

8

1 reference

2 October 2017

page(s)

1008-1016

1 reference

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

2 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

The global epidemiology of childhood pneumonia 20 years on.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Burden of pneumonia and meningitis caused by Streptococcus pneumoniae in China among children under 5 years of age: a systematic literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Novel Protein-Based Pneumococcal Vaccines Administered with the Th1-Promoting Adjuvant IC31 Induce Protective Immunity against Pneumococcal Disease in Neonatal Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Serotype-independent protection against pneumococcal infections elicited by intranasal immunization with ethanol-killed pneumococcal strain, SPY1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Mucosal and systemic immunization with a novel attenuated pneumococcal vaccine candidate confer serotype independent protection against Streptococcus pneumoniae in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Experience with registered mucosal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Recent progress in mucosal vaccine development: potential and limitations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Mast cell-orchestrated immunity to pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Critical protective role of mast cells in a model of acute septic peritonitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Mast cell activators: a new class of highly effective vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Stable dry powder formulation for nasal delivery of anthrax vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

A Mast Cell Degranulation Screening Assay for the Identification of Novel Mast Cell Activating Agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Histologic studies of human skin test responses to ragweed, compound 48-80, and histamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Analysis of compound 48/80-induced skin histamine release and leukotriene production in chronic urticaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

TLR-based immune adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Toll-like receptors as adjuvant receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Innate immunity to pneumococcal infection of the central nervous system depends on toll-like receptor (TLR) 2 and TLR4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Myeloid differentiation factor 88-dependent signalling controls bacterial growth during colonization and systemic pneumococcal disease in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Host and bacterial factors contributing to the clearance of colonization by Streptococcus pneumoniae in a murine model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Intranasal Administration of the TLR2 Agonist Pam2Cys Provides Rapid Protection against Influenza in Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Human lung mast cells mediate pneumococcal cell death in response to activation by pneumolysin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Interleukin-17A mediates acquired immunity to pneumococcal colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Regulation of murine in vivo IgG and IgE responses by a monoclonal anti-IL-4 receptor antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

IL-13 is necessary, not simply sufficient, for epicutaneously induced Th2 responses to soluble protein antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

IL-33-mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen-induced allergic airway inflammation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Cholera toxin prevents Th1-mediated autoimmune disease by inducing immune deviation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Rapidly changing perspectives about mast cells at mucosal surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

Immunoglobulin E-dependent active fatal anaphylaxis in mast cell-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.01.013

10.1016/J.VACCINE.2015.01.013

7 January 2021

Identifiers

DOI

1 reference

2 October 2017

1 reference